BME
—
—
Loading…
—
—
MASTER
—
—
ESEN VERDICT
Analyzing…
Horizon6–12M
Confidence—
Data coverage—
ESEN News Intelligence — BME
Sentiment: Neutral
Impact: Low
AI Summary: Limited recent news flow for BME as of August 14, 2026. One headline referencing passive income investment strategies was detected but lacks direct BME-specific content. The trust continues trading near recent highs (52-week: $35.28–$44.99) with a modest -0.94% daily decline. Material earnings, earnings guidance, or distribution announcements are not present in available coverage. Investors should monitor for upcoming ex-dividend dates and quarterly earnings releases.
Compliance Note: This summary reflects available public news as of 2026-08-14T16:57:56Z. Coverage for BME is currently constrained. This is not investment advice.
SNAPSHOT
Ticker
BME
Company
Blackrock Health Sciences Trust
Sector
Financials (Closed-End Fund)
Market Cap
$574.8M
Current Price
$44.13 ▼ -0.42 (-0.94%)
52W Range
$35.28 – $44.99
52W Return
+25.90%
Exchange
NYSE
EARNINGS MOMENTUM
| Metric | Latest Value | Assessment |
|---|---|---|
| EPS (TTM) | $5.96 | Strong absolute level |
| EPS Growth YoY | +273.85% | Exceptional acceleration |
| Revenue Growth YoY | +6.03% | Modest but stable |
| Forward P/E | Data not disclosed | Limited visibility on guidance |
| Earnings Date | Not available | Coverage constrained for CEF |
Commentary: BME exhibits hyper-growth earnings (273.85% YoY spike), driven by concentrated healthcare equity holdings. As a closed-end fund, reported EPS reflects net investment income and realized gains rather than traditional operational earnings. Revenue growth of 6.03% reflects modest expansion in managed assets or distributions. The absence of forward guidance is typical for CEFs. Earnings surprise history unavailable due to fund structure.
Earnings Momentum Score: 8.5/10 | Direction: Strong Upward | Caveat: EPS surge likely driven by market recovery in healthcare equities, not organic business growth
PROFITABILITY & QUALITY
| Metric | Value | Assessment |
|---|---|---|
| Gross Margin | N/A | Not applicable for CEF |
| Operating Margin | N/A | Not applicable for CEF |
| Net Profit Margin | Data not available | Inferred from EPS/NAV dynamics |
| ROE | Data not available | Portfolio performance metric more relevant |
| Flag: Strong Profitability | FALSE | EPS growth is volatility-driven, not sustainable operational strength |
| Dividend Yield | 7.13% | Attractive income distribution, typical for healthcare-focused CEF |
| Dividend Per Share | $3.15 | Well-covered by current EPS of $5.96 |
Commentary: As a closed-end fund, traditional profitability metrics are not meaningful. Quality should be assessed via portfolio composition, NAV performance, and expense ratio. The strong 7.13% dividend yield is attractive for income investors, and current distribution appears sustainable at 1.78x coverage (EPS/DPS). However, the fund's profitability is entirely dependent on healthcare sector equity performance and realized gains—not operational excellence.
Quality Score: 3.5/10 | Verdict: Moderate Concern | CEF quality is fund-dependent; healthcare sector concentration creates valuation and volatility risks
BALANCE SHEET HEALTH
| Metric | Value | Assessment |
|---|---|---|
| Cash | Data not available | Not meaningful for CEF portfolio funds |
| Total Debt | Data not available | CEF may use leverage; details not disclosed |
| Net Debt / EBITDA | N/A | Not applicable for investment funds |
| Current Ratio | N/A | Liquidity managed at fund level |
| Weak Balance Sheet Flag | FALSE | No red flags in available data |
| Fund Leverage / Gearing | Not disclosed | Critical metric for CEF risk; recommend reviewing prospectus |
| Portfolio NAV Trend | 52W return: +25.90% | Positive NAV growth, aligned with healthcare sector strength |
Commentary: Traditional balance sheet metrics are not applicable. BME's financial health depends on: (1) portfolio composition quality, (2) leverage levels (many CEFs use debt for yield enhancement), and (3) NAV stability. The 25.90% 52-week return suggests healthy portfolio performance. However, healthcare sector concentration and potential leverage create tail risks during sector downturns.
Balance Sheet Risk: Moderate | Verdict: CEF-appropriate structure; monitor leverage and sector concentration
VALUATION ANALYSIS
| Metric | BME | Interpretation |
|---|---|---|
| Trailing P/E | 7.41x | Extremely attractive on earnings basis |
| Forward P/E | Not available | Limited guidance visibility |
| PEG Ratio | 0.027 | Deeply undervalued relative to 273.85% earnings growth |
| P/S Ratio | Not available | Not applicable for fund structure |
| Price-to-Book (Implied) | Data not available | Check vs. NAV; trading discount/premium critical |
| Valuation Flag: High | FALSE | Valuation is attractive on traditional metrics |
| Beta | 0.593 | Lower volatility than broad market; healthcare focus |
Commentary: BME trades at a compelling 7.41x P/E with an extraordinary PEG of 0.027, suggesting deep undervaluation. However, this must be contextualized: (1) the 273.85% EPS surge is unsustainable, (2) earnings are mark-to-market portfolio gains, not recurring income, and (3) CEF valuations are most meaningfully assessed via price-to-NAV premium/discount, which is unavailable. The low beta of 0.593 reflects healthcare sector defensive characteristics. Valuation appears attractive on traditional metrics but requires NAV analysis for true CEF valuation.
Valuation Status: Attractively Priced | Score: 7.2/10 | Caveat: Traditional multiples misleading for CEF; assess price-to-NAV separately
ANALYST TARGETS & SENTIMENT
| Metric | Value | Status |
|---|---|---|
| Consensus Rating | Not available | Limited coverage typical for CEFs |
| Average Price Target | Not available | Data not disclosed |
| High Price Target | Not available | Data not disclosed |
| Low Price Target | Not available | Data not disclosed |
| Implied Upside | Unable to calculate | No consensus available |
| Analyst Dispersion | N/A | Insufficient coverage data |
Commentary: Closed-end funds typically receive minimal analyst coverage compared to operating companies. BME shows no published consensus ratings or price targets in available data. This is normal for CEFs and reflects their niche appeal to income-focused investors. Sentiment assessment must rely on fund flows, discount-to-NAV trends, and healthcare sector momentum rather than Wall Street consensus.
Wall Street Sentiment: Limited Data | Score: 4/10 | Verdict: Insufficient coverage; assess via fund flows and sector technicals
INSTITUTIONAL & RISK CHECK
| Risk Factor | Status | Assessment |
|---|---|---|
| Institutional Ownership | Not available | Data not disclosed; typical for CEF |
| Insider Activity | Not available | Limited relevance for closed-end fund |
| Short Interest | Not available | Data not available |
| Sector Concentration Risk | HIGH | Healthcare-only fund creates significant sector beta |
| Rate Sensitivity | MODERATE | Healthcare equities moderately sensitive to rate environment |
| Leverage/Gearing Risk | Unknown | Critical; many CEFs use leverage—review prospectus |
| Hyper-Growth Flag | TRUE | 273.85% YoY EPS growth—likely unsustainable |
| Red Flag: Concentration | PRESENT | Single-sector focus; 2020-2021 healthcare sell-off risk |
Commentary: Key risks for BME include: (1) Sector concentration—healthcare holdings alone create significant drawdown risk if sector rotates; (2) Unsustainable earnings growth—273.85% YoY growth is likely temporary due to prior-year comps and market rebound, not repeatable; (3) Leverage exposure—many CEFs employ borrowing to boost yield, amplifying downside risk; (4) Rate sensitivity—rising rates could pressure healthcare valuations and reduce demand for high-yield vehicles. Insider activity and institutional ownership data are not available, limiting sentiment assessment.
Risk Level: Elevated | Score: 6.5/10 | Primary Concerns: Sector concentration, earnings reversion, leverage (unknown)
FINAL ESEN VERDICT
65
Overall Fundamental Score (0–100)
Conviction Level:
Moderate-to-High | Suitable for income-focused investors with healthcare sector conviction
Moderate-to-High | Suitable for income-focused investors with healthcare sector conviction
Time Horizon Grid:
| Horizon | Outlook | Confidence |
|---|---|---|
| Short (1–3M) | Neutral-Bullish | Technical support at $43–$44 | Moderate |
| Medium (6–12M) | Bullish if healthcare outperforms | Target $48–$50 | Moderate |
| Long (2Y+) | Sector-dependent | Valuation compression risk if rates rise | Low-Moderate |
Final Summary:
- Valuation Appeal: BME trades at compelling 7.41x P/E with 0.027 PEG, attractive for deep-value hunters, but earnings growth (273.85% YoY) is unsustainable and mark-to-market driven.
- Income Strength: 7.13% dividend yield with 1.78x EPS coverage offers solid income, though sustainability depends on healthcare sector performance and fund leverage levels (not disclosed).
- Sector Risk: 100% healthcare concentration creates significant downside risk during sector rotations; unsuitable for diversification-focused portfolios or risk-averse investors.
- Growth Caveat: 273.85% EPS growth reflects healthcare equity market rebound and realized gains, not repeatable operational improvement; expect significant reversion in following periods.
- Recommendation: HOLD/CAUTIOUS BUY for income investors with (a) healthcare sector conviction, (b) 12+ month horizon, and (c) high risk tolerance. Not suitable for conservative or diversified allocations. Review prospectus for leverage and fee structure before investing.
AI STOCK INSIGHT
BME Stock Analysis & Forecast
Is BME a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
BME Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, BME shows balanced risk-reward characteristics.
Should You Buy BME Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in BME.